AbbVie looking for specialty deals

With 3Q14 earnings that beat guidance, AbbVie Inc. (NYSE:ABBV) CEO Richard Gonzalez said the pharma still has an appetite for M&A, but declared it's unlikely to find more $50 billion opportunities like the attempted inversion deal with Shire plc (LSE:SHP; NASDAQ:SHPG).

Gonzalez said AbbVie's performance shows "that we're a company that's in an even stronger position today than we were before we announced this deal." ...